# Korea Post Marketing Surveillance (PMS) Study of Vizimpro

> **NCT04721106** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 188 (actual)

## Conditions studied

- Lung Neoplasms

## Interventions

- **DRUG:** Vizimpro

## Key facts

- **NCT ID:** NCT04721106
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-07
- **Primary completion:** 2026-01-19
- **Final completion:** 2026-01-19
- **Target enrollment:** 188 (ACTUAL)
- **Last updated:** 2026-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04721106

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04721106, "Korea Post Marketing Surveillance (PMS) Study of Vizimpro". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT04721106. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*